Adynxx

Adynxx is a clinical-stage pharmaceutical company that is developing a technology platform for addressing pain at its molecular roots, treating the development of pain following a surgery or trauma and chronic pain syndromes.

Adynxx's pipeline of products includes brivoligide, a Phase 2 drug candidate that is intended to address postoperative pain, and AYX2, a pre-clinical candidate that is intended to treat chronic syndromes of pain—including inflammatory and neuropathic pain.

The company announced its merger with Alliqua BioMedicalin April 2019, with the stockholders of Adynxx to become the majority owners of Alliqua's outstanding common stock on a fully-diluted basis. It brought on board the post-op pain drug brivoligide.